Iatrogenic cutaneous lymphoid hyperplasia induced by squaric acid dibutyl ester

2021 ◽  
Author(s):  
Shunsuke Takahagi ◽  
Tomofumi Numata ◽  
Akio Tanaka ◽  
Michihiro Hide
2011 ◽  
Vol 65 (1) ◽  
pp. 230-232 ◽  
Author(s):  
Eric A. Millican ◽  
Jarod A. Conley ◽  
David Sheinbein

2021 ◽  
pp. 54-57
Author(s):  
Gyohei Egawa ◽  
Tetsuya Honda ◽  
Kenji Kabashima

Contact immunotherapy with several sensitizing chemicals such as diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE) have been used for the treatment of recalcitrant or multiple warts. Here, we report a case of multiple verrucae vulgaris (VV) on the palm which spontaneously resolved after the development of systemic contact dermatitis against alkyl bromide. We considered that our case accidentally mimics contact immunotherapy against multiple VV. VV sometimes regress spontaneously, which may be triggered by accidental contact dermatitis, as shown in our case.


2022 ◽  
Vol 0 ◽  
pp. 1-8
Author(s):  
Abel Francis ◽  
Anjali Rose Jose

Immunosuppressive drugs are the main stay of treatment for autoimmune dermatoses. The main disadvantage of these drugs is the increased susceptibility to life-threatening infections. Hence, in recent years, there has been an enthusiastic search for newer groups of drugs that can reduce this risk. Immune enhancing agents are considered as the key players of future. Immune enhancers function by activating various elements of the immune system and thereby amplifying the immune responses. They can be specific or non-specific in action. The main autoimmune dermatoses where the benefits of these drugs have so far been utilized include alopecia areata, vitiligo, psoriasis, lichen planus, and discoid lupus erythematosus. Immunostimulants are available in both topical and systemic forms. Topical immune- enhancing agents include contact sensitizers (diphenylcyclopropenone, dinitrochlorobenzene, and squaric acid dibutyl ester), anthralin, topical zinc, and interferons. Systemic agents include levamisole, zinc, probiotics, and so on. The exact mechanism of action of some of these drugs and other autoimmune conditions where they can be benefited is not completely understood. Another therapeutic agent that may come up in the future is individualized vaccines. Let us look forward to the days when individualized vaccines work wonders in the management of autoimmune diseases.


2019 ◽  
Vol 7 (1) ◽  
pp. 22-40 ◽  
Author(s):  
Hugh McTavish ◽  
Katherine W. Zerebiec ◽  
Jay C. Zeller ◽  
Laurie L. Shekels ◽  
Mark A. Matson ◽  
...  

2016 ◽  
Vol 176 (2) ◽  
pp. 491-494 ◽  
Author(s):  
L. Guerra ◽  
V. Pacifico ◽  
V. Calabresi ◽  
N. De Luca ◽  
D. Castiglia ◽  
...  

Dermatitis ◽  
2008 ◽  
Vol 19 (2) ◽  
pp. 95-99 ◽  
Author(s):  
Melissa M. Camouse ◽  
Alan R. Swick ◽  
Cindy A. Ryan ◽  
Ben Hulette ◽  
Frank Gerberick ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document